Phase 3 Readout~month

Phase 3 Topline: A Pivotal Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Stu

Name: Phase 3 Topline: A Pivotal Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Stu
Start: 2030-08-01

August 1, 2030

Company: Moleculin Biotech, Inc. (MBRX)
Drug: cytarabine
Indication: Acute Myeloid Leukaemia (AML)

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Pivotal Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Stu — MBRX Phase 3 Readout | BioSniper